All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

Customizing first-line BTK inhibitors for CLL

with Gilles Salles, Paolo Ghia, and Francesc Bosch

Wednesday, October 23, 2024
18:30-19:30 BST

Register now

This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.

Brought to you by

Scientific Education Support logo
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

SubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2018-12-21T12:20:23.000Z

Loretta Nastoupil | ASH 2018 | Real world outcomes of axi-cel

By Philippa Redondo
Featured
Loretta Nastoupil
Dec 21, 2018
Share:

60th ASH Annual Meeting & Exposition, December 1-4 2018, San Diego, CA
Loretta Nastoupil
MD Anderson Cancer Center, Houston, US

Interview Topic: Real world outcomes of axi-cel

Loretta Nastoupil | ASH 2018 | Real world outcomes of axi-cel

More about...
Aggressive B-cell lymphomasASH 2018Axicabtagene ciloleucelDiffuse large B-cell lymphomaZUMA-1

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
3 votes - 65 days left ...

Related articles

Add bookmark

Frederick Locke | ASH 2018 | ASH 2018 CAR-T updates in B-cell malignancies

Frederick Locke, from the H. Lee Moffitt Cancer Center and Research Institute, discusses CAR T updates in B-cell malignancies at ASH 2018.

Dec 21, 2018
Add bookmark

Frederick Locke | ASH 2018 | ASH 2018 CAR-T updates in B-cell malignancies

Frederick Locke, from the H. Lee Moffitt Cancer Center and Research Institute, discusses CAR T updates in B-cell malignancies...

Dec 21, 2018
Add bookmark

ASH 2018 | Real-world efficacy and safety outcomes with axi-cel in patients with relapsed/refractory large B-cell lymphoma comparable to the ZUMA-1 clinical trial

The study evaluated the real-world outcomes of patients treated with standard of...

Dec 3, 2018
Add bookmark

ASH 2018 | Real-world efficacy and safety outcomes with axi-cel in patients with relapsed/refractory large B-cell lymphoma comparable to the ZUMA-1 clinical trial

The study evaluated the real-world...

Dec 3, 2018

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox